Human Biclonics® for Superior Clinical Efficacy

Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.


Biclonics® retain the format of antibodies that are produced naturally by the immune system, retaining their favorable attributes including stability and predictability during manufacturing and long half-life and low immunogenicity during treatment of patients. Learn more about our technology


Our pipeline comprises Biclonics® for solid and hematological tumors that target combinations of growth factor receptors and immunomodulatory molecules. See what's in our pipeline


We make our technologies available in partnerships based on promising target combinations. Please contact us for further information.


MCLA-128 Shows Favorable Safety Profile and Early Signs of Anti-Tumor Activity in Patients with Advanced Solid Tumors UTRECHT, The Netherlands, April 15,...
Jefferies Immuno-Oncology Summit April 7-8, 2016 Boston, Massachusetts, USA The annual Jefferies Immuno-Oncology Summit will be held at the Boston Harbor...
Utrecht, The Netherlands, March 9, 2016 — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics,...